Human iPSC Modeling Reveals Mutation-Specific Responses to Gene Therapy in a Genotypically Diverse Dominant Maculopathy.

Abstract

Dominantly inherited disorders are not typically considered to be therapeutic candidates for gene augmentation. Here, we utilized induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) to test the potential of gene augmentation to treat Best disease, a dominant macular dystrophy caused by over 200 missense mutations in BEST1. Gene augmentation in iPSC-RPE fully restored BEST1 calcium-activated chloride channel activity and improved rhodopsin degradation in an iPSC-RPE model of recessive bestrophinopathy as well as in two models of dominant Best disease caused by different mutations in regions encoding ion-binding domains. A third dominant Best disease iPSC-RPE model did not respond to gene augmentation, but showed normalization of BEST1 channel activity following CRISPR-Cas9 editing of the mutant allele. We then subjected all three dominant Best disease iPSC-RPE models to gene editing, which produced premature stop codons specifically within the mutant BEST1 alleles. Single-cell profiling demonstrated no adverse perturbation of retinal pigment epithelium (RPE) transcriptional programs in any model, although off-target analysis detected a silent genomic alteration in one model. These results suggest that gene augmentation is a viable first-line approach for some individuals with dominant Best disease and that non-responders are candidates for alternate approaches such as gene editing. However, testing gene editing strategies for on-target efficiency and off-target events using personalized iPSC-RPE model systems is warranted. In summary, personalized iPSC-RPE models can be used to select among a growing list of gene therapy options to maximize safety and efficacy while minimizing time and cost. Similar scenarios likely exist for other genotypically diverse channelopathies, expanding the therapeutic landscape for affected individuals.

• Authors: Divya Sinha, Benjamin Steyer, Pawan K Shahi, Katherine P Mueller, Rasa Valiauga, Kimberly L Edwards, Cole Bacig, Stephanie S Steltzer, Sandhya Srinivasan, Amr Abdeen, Evan Cory, Viswesh Periyasamy, Alireza Fotuhi Siahpirani, Edwin M Stone, Budd A Tucker, Sushmita Roy, Bikash R Pattnaik, Krishanu Saha, David M Gamm
• Journal: American journal of human genetics (Am J Hum Genet) Vol. 107 Issue 2 Pg. 278-292 (08 06 2020) ISSN: 1537-6605 [Electronic] United States
• PMID: 32707085 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2020 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Chemical References

• Bestrophins
• Eye Proteins
• Calcium

Topics

• Alleles
• Bestrophins (genetics)
• Calcium (metabolism)
• Cell Line
• Channelopathies (genetics)
• Eye Proteins (genetics)
• Gene Editing (methods)
• Genetic Therapy (methods)
• Genotype
• HEK293 Cells
• Humans
• Induced Pluripotent Stem Cells (physiology)
• Macular Degeneration (genetics)
• Mutation (genetics)
• Retinal Pigment Epithelium (physiology)